Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306).
Liu L, Erickson NT, Ricard I, von Weikersthal LF, Lerch MM, Decker T, Kiani A, Kaiser F, Heintges T, Kahl C, Kullmann F, Scheithauer W, Link H, Höffkes HG, Moehler M, Gesenhues AB, Theurich S, Michl M, Modest DP, Algül H, Stintzing S, Heinemann V, Holch JW.
Liu L, et al. Among authors: moehler m.
Int J Cancer. 2022 Jan 1;150(1):112-123. doi: 10.1002/ijc.33775. Epub 2021 Sep 6.
Int J Cancer. 2022.
PMID: 34431518
Clinical Trial.